2 results
Not approvedWill not start
Primary:Long-term safety of nivolumab in participants on treatment and in follow upExploratory:To follow participants who have completed therapy and are in or have completed follow-up on a parent study investigating nivolumab or nivolumab…
Approved WMOCompleted
Primary objective:To demonstrate the non-inferiority (NI) of the humoral immune response in healthy participants 50-59 YOA compared to OA (>=60 YOA) for the RSV-A strain after RSVPreF3 OA investigational vaccine administration.To demonstrate…